-DOCSTART- -X- O
To -X- _ O
determine -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
biomarkers -X- _ O
in -X- _ O
the -X- _ O
clinical -X- _ O
management -X- _ O
of -X- _ O
respiratory -X- _ B-Patient
complications -X- _ I-Patient
( -X- _ I-Patient
RC -X- _ I-Patient
) -X- _ I-Patient
in -X- _ I-Patient
hematopoietic -X- _ I-Patient
stem -X- _ I-Patient
cell -X- _ I-Patient
transplantation -X- _ I-Patient
( -X- _ I-Patient
HSCT -X- _ I-Patient
) -X- _ I-Patient
recipients -X- _ I-Patient
, -X- _ O
we -X- _ O
have -X- _ O
prospectively -X- _ O
evaluated -X- _ O
a -X- _ O
cohort -X- _ O
of -X- _ O
175 -X- _ O
patients -X- _ O
followed-up -X- _ O
for -X- _ O
1 -X- _ O
year -X- _ O
after -X- _ O
HSCT. -X- _ O
To -X- _ O
avoid -X- _ O
misinterpretation -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
excluded -X- _ O
both -X- _ O
unidentified -X- _ O
respiratory -X- _ O
infections -X- _ O
( -X- _ O
RI -X- _ O
) -X- _ O
and -X- _ O
mixed -X- _ O
RI. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
64 -X- _ B-Patient
RC -X- _ I-Patient
were -X- _ O
included. -X- _ O
Plasma -X- _ O
levels -X- _ O
of -X- _ O
C-reactive -X- _ O
protein -X- _ O
( -X- _ O
CRP -X- _ O
) -X- _ O
, -X- _ O
procalcitonin -X- _ O
( -X- _ O
PCT -X- _ O
) -X- _ O
and -X- _ O
proadrenomedullin -X- _ O
( -X- _ O
proADM -X- _ O
) -X- _ O
were -X- _ O
measured -X- _ O
at -X- _ O
diagnosis -X- _ O
and -X- _ O
on -X- _ O
day -X- _ O
3 -X- _ O
and -X- _ O
7. -X- _ O
Different -X- _ O
cytokines -X- _ O
were -X- _ O
evaluated -X- _ O
in -X- _ O
serum -X- _ O
on -X- _ O
the -X- _ O
first -X- _ O
day. -X- _ O
No -X- _ B-Comparison
HSCT -X- _ I-Comparison
recipients -X- _ I-Comparison
without -X- _ I-Comparison
RC -X- _ I-Comparison
were -X- _ O
included -X- _ O
as -X- _ O
a -X- _ O
control -X- _ O
group. -X- _ O
Compared -X- _ B-Outcome
with -X- _ I-Outcome
RI -X- _ I-Outcome
, -X- _ I-Outcome
non-infectious -X- _ I-Outcome
RC -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
CRP -X- _ I-Outcome
, -X- _ I-Outcome
proADM -X- _ I-Outcome
and -X- _ I-Outcome
interleukin -X- _ I-Outcome
6 -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
0 -X- _ I-Outcome
( -X- _ I-Outcome
P=0.005 -X- _ I-Outcome
; -X- _ I-Outcome
P=0.03 -X- _ I-Outcome
and -X- _ I-Outcome
P=0.04 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
When -X- _ I-Outcome
only -X- _ I-Outcome
RI -X- _ I-Outcome
were -X- _ I-Outcome
considered -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
observed -X- _ I-Outcome
that -X- _ I-Outcome
bacterialâ€“fungal -X- _ I-Outcome
PI -X- _ I-Outcome
showed -X- _ I-Outcome
higher -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
CRP -X- _ I-Outcome
( -X- _ I-Outcome
P=0.02 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
PCT -X- _ I-Outcome
( -X- _ I-Outcome
P=0.04 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
proADM -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Persistent -X- _ I-Outcome
low -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
proADM -X- _ I-Outcome
biomarkers -X- _ I-Outcome
suggest -X- _ I-Outcome
viral -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
specificity -X- _ I-Outcome
and -X- _ I-Outcome
positive -X- _ I-Outcome
predictive -X- _ I-Outcome
value -X- _ I-Outcome
100 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Patients -X- _ I-Outcome
dying -X- _ I-Outcome
of -X- _ I-Outcome
RC -X- _ I-Outcome
had -X- _ I-Outcome
PCT -X- _ I-Outcome
and -X- _ I-Outcome
proADM -X- _ I-Outcome
levels -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
survivors -X- _ I-Outcome
( -X- _ I-Outcome
P=0.002 -X- _ I-Outcome
and -X- _ I-Outcome
P=0.03 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
HSCT -X- _ I-Outcome
recipients -X- _ I-Outcome
biomarkers -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
infectious -X- _ I-Outcome
and -X- _ I-Outcome
non-infectious -X- _ I-Outcome
RC. -X- _ I-Outcome
They -X- _ O
may -X- _ O
have -X- _ O
utility -X- _ O
in -X- _ O
the -X- _ O
assessment -X- _ O
of -X- _ O
the -X- _ O
severity -X- _ O
of -X- _ O
RC -X- _ O
and -X- _ O
in -X- _ O
suspecting -X- _ O
a -X- _ O
viral -X- _ O
etiology. -X- _ O
SUPPLEMENTARY -X- _ O
INFORMATION -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
doi:10.1038 -X- _ O
/ -X- _ O
bmt.2016.280 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

